On September 23, 2020 Viva Biotech reported that it is putting down $80 million to buy preclinical contract research organization SYNthesis and boost its outsourcing business (Press release, Vivia Biotech, SEP 23, 2020, View Source [SID1234565573]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Hong Kong-based SYNthesis is a preclinical small-molecule drug discovery service contract organization selling pharmaceutical chemistry and synthetic chemistry services to its clients.
Headquartered in Hong Kong, it also has service platforms in Suzhou in Shanghai and Australia as well as offices in the U.K. and the U.S.; a part of its plan is to broaden its geographic reach.
Reducing Time to Clinic for Your Biomedical Applications
Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.
Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure GelMA can help you in your developments.
DOWNLOAD FOR FREE
It will now fall under the umbrella of Shanghai-based Viva Biotech, an integrated drug discovery platform focused on preclinical-stage innovative drug development, covering the full spectrum of our customers’ needs for early-stage drug discovery.
"We are very delighted to achieve the strategic acquisition agreement with SYNthesis. We believe that SYNthesis’s technical platform and international team in the field of pharmaceutical chemistry and synthetic chemistry will quickly strengthen the capabilities of Viva Biotech from early drug discovery service to drug R & D downstream business, as well as boost The Company’s downstream integration to CMC and CDMO fields," said Cheney Mao, Ph.D., chairman and CEO of Viva.
"I am thrilled and delighted to have my team at SYNthesis join forces with the Viva team," added Xian Bu, Ph.D., managing director of SYNthesis. "Our preclinical small molecule pharmaceutical chemistry platform will be organically combined with the structure-based drug discovery and bioassay platforms of Viva Biotech, to provide a comprehensive preclinical R&D services for more customers. Together we will become a force to be reckoned with in the high-end medicinal chemistry space."